Trial reportThe American journal of psychiatry2017
Patient Expectancy as a Mediator of Placebo Effects in Antidepressant Clinical Trials.
Trial report in The American journal of psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 5 syntheses or guidelines pooled it, 159 citations in OpenAlex.
- Machine learning approaches in the therapeutic outcome prediction in major depressive disorder: a systematic review.Frontiers in psychiatry · 2025Pooled it
- Side-effects of mdma-assisted psychotherapy: a systematic review and meta-analysis.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Pooled it
- Placebo and nocebo effects and mechanisms associated with pharmacological interventions: an umbrella review.BMJ open · 2023Pooled it
- Differential power of placebo across major psychiatric disorders: a preliminary meta-analysis and machine learning study.Scientific reports · 2021Pooled it
- Predictors of Placebo Response in Pharmacological Clinical Trials of Negative Symptoms in Schizophrenia: A Meta-regression Analysis.Schizophrenia bulletin · 2019Pooled it
- Intermittent Theta-Burst Stimulation and Depressive Symptoms in Major Depressive Disorder: A Randomized Clinical Trial.JAMA network open · 2026Trial
- Oral Prolonged-Release Ketamine for Treatment-Resistant Depression: Two Randomized Clinical Trials.JAMA network open · 2026Trial
- Brain functional basis of the association between positive expectation and acupuncture efficacy in knee osteoarthritis.Brain imaging and behavior · 2026Trial
- Effects of antidepressant medications on brain tissue microstructure in persistent depressive disorder across two randomized controlled trials.NeuroImage. Clinical · 2026Trial
- Lack of association between pretreatment glutamate/GABA and major depressive disorder treatment response.Translational psychiatry · 2025Trial
- Efficacy and safety of intravenous ketamine treatment in Japanese patients with treatment-resistant depression: A double-blind, randomized, placebo-controlled trial.Psychiatry and clinical neurosciences · 2024Trial
- Predictive values of pre-treatment brain age models to rTMS effects in neurocognitive disorder with depression: Secondary analysis of a randomised sham-controlled clinical trial.Dialogues in clinical neuroscience · 2024Trial
- Expectancy Does Not Predict 18-month Treatment Outcomes with Cognitive Training in Mild Cognitive Impairment.The journal of prevention of Alzheimer's disease · 2024Trial
- Clinical and radiomic features for predicting the treatment response of repetitive transcranial magnetic stimulation in major neurocognitive disorder: Results from a randomized controlled trial.Human brain mapping · 2022Trial
- μ Opioid Antagonist Naltrexone Partially Abolishes the Antidepressant Placebo Effect and Reduces Orbitofrontal Cortex Encoding of Reinforcement.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2021Trial
- Who benefits most from expectancy effects? A combined neuroimaging and antidepressant trial in depressed older adults.Translational psychiatry · 2021Trial
- Slowed Processing Speed Disrupts Patient Expectancy in Late Life Depression.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2021Trial
- A Sequential Multiple Assignment Randomized Trial (SMART) study of medication and CBT sequencing in the treatment of pediatric anxiety disorders.BMC psychiatry · 2021Trial
- Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disorders.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021Trial
- Probiotics as a treatment for prenatal maternal anxiety and depression: a double-blind randomized pilot trial.Scientific reports · 2021Trial
15 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
objectiveCauses of placebo effects in antidepressant trials have been inferred from observational studies and meta-analyses, but their mechanisms have not been directly established. The goal of this study was to examine in a prospective, randomized controlled trial whether patient expectancy mediates placebo effects in antidepressant studies.
methodAdult outpatients with major depressive disorder were randomly assigned to open or placebo-controlled citalopram treatment. Following measurement of pre- and postrandomization expectancy, participants were treated with citalopram or placebo for 8 weeks. Independent samples t tests determined whether patient expectancy differed between the open and placebo-controlled groups, and mixed-effects models assessed group effects on Hamilton Depression Rating Scale (HAM-D) scores over time while controlling for treatment assignment. Finally, mediation analyses tested whether between-group differences in patient expectancy mediated the group effect on HAM-D scores.
resultsPostrandomization expectancy scores were significantly higher in the open group (mean=12.1 [SD=2.1]) compared with the placebo-controlled group (mean=11.0 [SD=2.0]). Mixed-effects modeling revealed a significant week-by-group interaction, indicating that HAM-D scores for citalopram-treated participants declined at a faster rate in the open group compared with the placebo-controlled group. Patient expectations postrandomization partially mediated group effects on week 8 HAM-D.
conclusionsPatient expectancy is a significant mediator of placebo effects in antidepressant trials. Expectancy-related interventions should be investigated as a means of controlling placebo responses in antidepressant clinical trials and improving patient outcome in clinical treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.